Posted on 8/24/17
Johnson & Johnson Is Doing Just Fine
A growing number of investors seem to believe that Johnson & Johnson (JNJ) is overvalued after seeing some relatively weak financial results. The combination of a . . .
Posted on 8/24/17
How Johnson & Johnson Makes Most of Its Money
As you might expect, Johnson & Johnson (NYSE:JNJ) makes a lot of money. Last year, the healthcare giant generated revenue totaling nearly $72 billion. Over the . . .
Posted on 8/23/17
What's Next for Bristol-Myers Squibb After Its Opdivo Setback?
The signs were definitely there for a disappointment from Bristol-Myers Squibb (NYSE:BMY). Several weeks ago, AstraZeneca (NYSE:AZN) reported its checkpoint inhibitor Imfinzi failed to improve progression-free . . .
Posted on 8/23/17
Pfizer: Pharma Dividend Superstar
Pfizer Inc. (NYSE:PFE) stock comes with a rather formidable dividend yield of 3.92 percent, which, coupled with a strong growth rate, makes it one of the . . .
Posted on 8/23/17
What Will Drive Regeneron Pharmaceuticals' Growth Higher From Here?
Regeneron Pharmaceuticals' (NASDAQ:REGN) $5 billion in sales in 2016 were due mostly to sales of its top-selling vision-restoring drug Eylea. However, a slate of newly Food . . .
Posted on 8/23/17
What's the Most Important Drug in Regeneron Pharmaceuticals' Pipeline?
Regeneron Pharmaceuticals (NASDAQ:REGN) has four significant medications on the market, including three that have won Food and Drug Administration approval since 2015, and it's investing big . . .
Posted on 8/22/17
Pfizer: Investors Are Missing The True Impact Of Xtandi
Investment ThesisPfizer (NYSE:PFE) performed satisfactorily in Q2 2017, although investors have not had any meaningful top line growth in for more than a decade. Its operational . . .
Posted on 8/22/17
Better Buy: AbbVie Inc. vs. Pfizer Inc.
There's no question that AbbVie (NYSE:ABBV) shareholders have been happier campers than Pfizer (NYSE:PFE) shareholders in recent years. Whether you compare the two drug stocks over . . .
Posted on 8/22/17
Champions Oncology Announces Strategic Collaboration with AstraZeneca
Champions Oncology, Inc. (NASDAQ: CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of . . .
Posted on 8/21/17
CURE Media Group Expands Strategic Alliance Partnership Program with Hope for Stomach Cancer
CRANBURY, N.J.--(BUSINESS WIRE)--CURE Media Group,the nation’s leading consumer digital and print media enterprise focused entirely on patients with cancer, is excited to welcome Hope for Stomach . . .
Posted on 8/21/17
J & J on the Hook for $417M in California Talcum Powder Case
Johnson & Johnson (NYSE:JNJ) is on the losing end of a jury verdict in California in a court case involving a woman who claimed that the . . .
Posted on 8/21/17
OmniSeq and LabCorp Sign Exclusive Distribution Agreement and Series B Funding Commitment
BUFFALO, N.Y., Aug. 21, 2017 (GLOBE NEWSWIRE) -- OmniSeq, Inc., a molecular diagnostics subsidiary of the Roswell Park Cancer Institute, announced today that it has entered . . .
Posted on 8/21/17
Avista Healthcare Public Acquisition Corp. and Envigo International Holdings To Merge
Avista Healthcare Public Acquisition Corp. (NASDAQ: AHPA), a publicly traded special purpose acquisition company, and Envigo International Holdings, Inc.,
Posted on 8/21/17
3 Top Biotech Stocks Under $10
Cheap and junk don't have to go hand in hand. Sometimes, items that are inexpensive could still have tremendous potential for their values to increase. That . . .
Posted on 8/21/17
Pfizer Inc. 2017 Q2 - Results - Earnings Call Slides
The following slide deck was published by Pfizer Inc. in conjunction with their 2017 Q2 earnings call. 112'READ FULL ARTICLE HERE
Posted on 8/21/17
Snippet Roundup: Transparency For Straumann But A Black Box For Pfizer
Welcome to your weekly roundup of EP Vantage's snippets - short takes on smaller news items.This week, August 14 to 18, 2017, we had thoughts on . . .
Posted on 8/21/17
Pfizer Looks To Sneak In the Market Before Heavy Hitters
On Thursday, Pfizer (PFE) received FDA approval for its drug Besponsa to treat patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). This is a . . .
Posted on 8/21/17
Here's How Much $10,000 Invested in Pfizer in 1977 Is Worth Now
Forty years is a long time. But it's not an unimaginably long time. For many Americans, 40 years is roughly the length of time they will . . .
Posted on 8/21/17
Pfizer's Besponsa Is Yet Another Win for the Biopharma Giant
Pfizer, Inc. (NYSE:PFE) scored another cancer drug victory this past week when the FDA green-lighted Besponsa, a drug that battles back against a rare and deadly . . .
Posted on 8/21/17
Is Regeneron Pharmaceuticals the Best Biotech Stock to Buy?
It may not get the attention as often as larger-cap biotech stocks like Celgene Corp. (NASDAQ:CELG) and Gilead Sciences (NASDAQ:GILD), but a bunch of recent drug . . .
Posted on 8/20/17
Champions Oncology Announces Research Collaboration with The Addario Lung Cancer Medical Institute
Champions Oncology, Inc. (NASDAQ: CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of . . .
Posted on 8/18/17
Is Regeneron Pharmaceuticals the Best Biotech Stock to Buy?
It may not get the attention as often as larger-cap biotech stocks like Celgene Corp. (NASDAQ:CELG) and Gilead Sciences (NASDAQ:GILD), but a bunch of recent drug . . .
Posted on 8/18/17
How Safe Is Johnson & Johnson's Dividend?
Johnson & Johnson (NYSE:JNJ) is one of the best-known companies in America, with most consumers making its over-the-counter products a staple of their medicine cabinets. Yet . . .
Posted on 8/17/17
Bristol-Myers Squibb Combination Treatment Not At The End Of The Crossroad
Bristol-Myers Squibb (BMY) announced results for its combination treatment treating patients with metastatic renal cell carcinoma (kidney cancer). The company reported mixed results in after-hours trade . . .
Posted on 8/17/17
Stryker’s Spine Division Receives FDA Clearance for Serrato Pedicle Screw
ALLENDALE, N.J.--(BUSINESS WIRE)--Stryker’s Spine division today announced that its Serrato™ Pedicle Screw, intended for use in the non-cervical spine as part of the company’s successful Xia® . . .

